Affymax Earns Takeda Milestone

Affymax will receive a $5 million development milestone payment from Takeda Pharmaceutical under the companies’ global development and commercialization agreement for peginesatide. The milestone is triggered by the EMA acceptance of the MAA for the investigational compound peginesatide for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.
 
“We are delighted with Takeda’s execution on the European front and are encouraged by the EMA acceptance of the MAA,” said John Orwin, president and chief executive officer of Affymax. “While we are concurrently preparing for potential commercialization of peginesatide in the U.S., we are pleased that progress is being made to potentially make the product available outside the U.S.”
 
Peginesatide was discovered by Affymax, and if approved, will be co-marketed by Affymax and Takeda in the U.S. Takeda has commercialization rights in the EU.